Eden Prairie launches its own THC-infused gummy and asks residents to name it
The mixed berry-flavored edible will hit the shelves this fall, and adults 21 and older who live in the southwest Twin Cities suburb have until next Wednesday to submit their ideas.
Eden Prairie Liquor has been selling the hemp-derived THC drinks since the Minnesota Legislature authorized their sales back in 2022 — a full year before lawmakers later legalized hemp's cannabis cousin, marijuana, for recreational use.
Those drinks are popular, said Jaime Urbina, liquor operations manager. But the three city-owned stores just started selling gummies earlier this year.
"One of the comments that we still get and feedback from customers are like, 'Oh, we were unaware that you have gummies now.'" Urbina explained. "We took this as an opportunity, as, like a marketing opportunity, to actually get it out there that we have a gummy and that we're bringing gummies in [to the stores]."
But the high interest in the naming contest for their own brand of gummy exceeded expectations, he said. There have been an average of about 90 entries each day in the last week since they invited residents to provide their feedback, for a total of roughly 680 entries so far.
Whoever wins gets bragging rights and a free package of gummies.
Among the entries so far: Prairie Berry, EP Sleepy, Berry in the Prairie.
"The contest ties in and gives a little bit more value to the community, so people are more involved with this entire process," Urbina said. "I think that's always a good thing for us and the residents."
Eden Prairie Liquor staff will narrow the list of entries to the top three names. There are some ground rules: no political slogans, no profanity and no individual person's name. Only residents can submit.
They will share that list on the Eden Prairie Liquor Facebook page on Aug. 4 for the public to weigh in before the winner is notified on Aug. 11. Everyone else will learn of the name that week, before the gummies are available to purchase in the fall.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Axios
an hour ago
- Axios
Texas Senate passes bill banning delta-8 THC
The Texas Senate on Tuesday advanced a bill banning delta-8 THC in consumable products while allowing low, nonintoxicating levels of THC and CBD to stay on the market. Why it matters: If the bill becomes law, it would impact Texas business owners who produce THC variants and would remove the products from shelves statewide. Driving the news: The bill passed 22-8 on its final reading Tuesday with no deliberation on the floor, just days into the second special legislative session called by Gov. Greg Abbott this year. Flashback: After passing the Senate in the first special session, the bill died when House Democrats broke quorum in protest of Abbott's push for congressional redistricting. Catch up quick: The 2019 Texas farm bill legalized 0.3% THC in consumable products like vapes, edibles and bud. The bill also legalized chemical variations of THC, like delta-8. Lt. Gov. Dan Patrick has pushed for a full ban on hemp-derived consumable products, which passed both the Texas Senate and House during the regular legislative session this spring.
Business Wire
6 days ago
- Business Wire
Organigram Reports Record Third Quarter Fiscal 2025 Results
TORONTO--(BUSINESS WIRE)--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the 'Company' or 'Organigram'), Canada's #1 cannabis company by market share 1, is pleased to announce its record results for the third quarter ended June 30, 2025 ('Q3 Fiscal 2025' or 'Q3'). Q3 FISCAL 2025 HIGHLIGHTS Record Gross Revenue: $110.2 million (+73% year-over-year, +7.2% sequential). Record Net Revenue: $70.8 million (+72% year-over-year, +7.9% sequential). International Revenue: $7.4 million (+208% year-over-year, +21% sequential). Adjusted EBITDA 2: $5.7 million (+64% year-over-year, +16% sequential). Free Cash Flow 2: $5.0 million versus ($4.8) million in the prior year period. Motif Synergies: $4.2 million to date, approximately $11 million annualized; on track to hit $15 million target within 24 months of acquisition. Total Cash: $85.9 million 3, including $35.9 million of unrestricted cash; and negligible debt. #1 Market Share in Canada: #1 in vapes, #1 in pre-rolls, #1 in milled flower, #1 in concentrates, #3 in edibles, #3 in dried flower 1. Canadian Beverage Growth: Expanded distribution in Alberta, Saskatchewan, and Manitoba. U.S. Expansion: Began generating U.S. revenue, expanded distribution into new states and gained important key account listings; launched U.S. DTC (direct-to-consumer) website expanding hemp-derived THC beverage availability to 25 states subsequent to quarter end. Record Moncton Harvest: of 24,210 kilograms, driven by capacity enhancing projects and seed-based cultivation; entire Moncton facility harvest averaged over 29% THC potency. 'In Q3, we delivered our second consecutive quarter of record revenue driven by the acquisition of Motif, Collective Project, and a further optimization of our product and brand portfolio,' said Beena Goldenberg, CEO of Organigram. 'With our strong Canadian market leadership now in place, we are committed to bringing our Canadian successes, underpinned by innovation and a commitment to quality, to international markets. We have grown our export business, expanded into the US, and are set to launch new brands internationally, all building towards our ambition of becoming a truly global cannabis player.' THIRD QUARTER FISCAL 2025 FINANCIAL OVERVIEW Net revenue: Net revenue increased 72% to $70.8 million, from $41.1 million in the third quarter ended June 30, 2024 ('Q3 Fiscal 2024'), primarily driven by contributions from the Motif Labs Ltd. ('Motif') acquisition and increased international sales. Adjusted gross margin 2: Adjusted gross margin was $24.2 million, or 34% of net revenue, compared to $14.6 million, or 36%, in Q3 Fiscal 2024. Organigram's standalone adjusted gross margin excluding Motif was approximately 37% in Q3. Management expects adjusted gross margin to improve over the coming quarters as Motif acquisition-related synergies are realized. Selling, general & administrative ('SG&A') expenses: SG&A increased 70% to $24.5 million from $14.4 million in Q3 Fiscal 2024. The increase was attributable to the inclusion of Motif SG&A in Organigram's consolidated financials as well as higher trade investments to support the growth of the business. As a proportion of net revenue, SG&A remained flat at 35%, compared to 35% in Q3 Fiscal 2024. Included in SG&A was an incremental investment of $1.2 million into ERP versus the prior year and higher amortization of $1.6 million associated with Motif and Collective Project Limited ('Collective Project') acquisitions. Net loss: Net loss was $6.3 million compared to net income of $2.8 million in Q3 Fiscal 2024. The decrease in net income from the prior period is primarily attributable to higher fair value changes recognized in relation to the preferred shares and top-up-rights held by British American Tobacco p.l.c ('BAT'), and other financial instruments. Adjusted EBITDA 4: Adjusted EBITDA was $5.7 million compared to $3.5 million in adjusted EBITDA in Q3 Fiscal 2024. The increase was primarily attributable to higher recreational revenue, including Motif contributions, and higher international revenue. Net cash from operating activities: Net cash from operating activities was $14.6 million, compared to cash used of $3.7 in Q3 Fiscal 2024. The increase was primarily attributable to improved working capital utilization. 'In Q3 we delivered solid revenue and adjusted EBITDA growth sequentially and year-over-year while making significant progress toward the full integration of our recent acquisitions,' said Greg Guyatt, CFO of Organigram. 'As our business continues to scale domestically and abroad, and the realization of cost synergies related to our Motif acquisition begin to positively impact future earnings, we are confident in our trajectory toward sustained profitability and free cash flow in the near-term.' CANADIAN RECREATIONAL MARKET INTRODUCTIONS As Canada's market leader in recreational cannabis, Organigram remains committed to delivering consumer focused innovations and products to its customers. Some notable recent highlights include: SHRED Max10 Party Pack: Ten individual 10mg gummies separately packaged within a container to provide consumers with 100mg THC per container. Big Bag O' Buds: New strains in Blueberry Dream, UK Cheddar Cheese, and Comboz (Ultra Sour & Blueberry Dream). SHRED Flower Power: The return of the OG SHRED blend — A sativa blend boasting strong sweet and floral aromas. BOXHOT IPRs: Pear Herer & Strawberry Diesel infused pre-rolls. Trailblazer Blunts: Tube-style blunts wrapped in tea leaf-based blunt paper for a smooth and unique flavour profile. Rizzlers Vapes: Lime Frizz & Passion Plunge all-in-one switch-hit vapes. INTERNATIONAL SALES In Q3 Fiscal 2025, Organigram achieved $7.4 million in international sales compared to $2.4 million in the same prior year period, and expects to continue growing its international sales over time. Organigram continues to await EU-GMP certification for its Moncton facility. In Q3 Fiscal 2025, Organigram began generating U.S. recreational revenue from hemp-derived THC beverage pursuant to the acquisition of Collective Project. BALANCE SHEET & LIQUIDITY As of June 30, 2025, the Company had total cash (including restricted cash and short-term investments) of $85.9 million. Select Key Financial Metrics (in $000s unless otherwise indicated) Q3-2025 Q3-2024 % Change Gross revenue 110,205 63,605 73 % Excise taxes (39,413 ) (22,545 ) 75 % Net revenue 70,792 41,060 72 % Cost of sales 48,369 27,173 78 % Gross margin before fair value changes to biological assets & inventories sold 22,423 13,887 61 % Realized fair value on inventories sold and other inventory charges (14,461 ) (13,728 ) 5 % Unrealized gain on changes in fair value of biological assets 18,184 13,849 31 % Gross margin 26,146 14,008 87 % Adjusted gross margin (1) 24,226 14,586 66 % Adjusted gross margin % (1) 34 % 36 % (2 )% Selling (including marketing), general & administrative expenses 24,504 14,376 70 % Net (loss) income (6,294 ) 2,818 nm Adjusted EBITDA (1) 5,694 3,465 64 % Net cash used in operating activities before working capital changes (686 ) (182 ) 277 % Net cash provided by (used in) operating activities after working capital changes 14,626 (3,730 ) nm Note (1) Adjusted gross margin, adjusted gross margin % and adjusted EBITDA are non-IFRS financial measures not defined by and do not have any standardized meaning under IFRS and might not be comparable to similar financial measures disclosed by other issuers; please refer to 'Non-IFRS Financial Measures' in this press release for more information. Expand Select Balance Sheet Metrics (in $000s) JUNE 30, 2025 SEPTEMBER 30, 2024 % Change Cash & short-term investments (including restricted cash) 85,931 133,426 (36 )% Biological assets & inventories 125,186 82,524 52 % Other current assets 66,666 46,269 44 % Accounts payable & accrued liabilities 89,803 47,097 91 % Current portion of long-term debt 40 60 (33 )% Working capital 170,508 208,897 (18 )% Property, plant & equipment 123,537 96,231 28 % Long-term debt — 25 (100 )% Total assets 564,615 407,860 38 % Total liabilities 179,119 101,871 76 % Shareholders' equity 385,496 305,989 26 % Expand The following table reconciles the Company's adjusted EBITDA to net loss. Adjusted EBITDA Reconciliation (in $000s unless otherwise indicated) Q3-2025 Q3-2024 Net (loss) income as reported $ (6,294 ) $ 2,818 Add/(deduct): Investment income, net of financing costs (73 ) (1,179 ) Income tax (recovery) expense (9,903 ) — Depreciation and amortization 4,789 3,039 ERP implementation costs 1,217 7 Acquisition and other transaction costs 654 421 Inventory and biological assets fair value and NRV adjustments (2,787 ) 578 Acquisition-related fair value adjustment to inventory sold 897 — Share-based compensation 1,007 2,087 Other (income) expenses(1) 13,511 (6,687 ) Research and development expenditures, net of depreciation 2,676 2,381 Adjusted EBITDA $ 5,694 $ 3,465 Note 1: Other (income) expenses includes share of loss from investments in associates, (gain) loss on disposal of property, plant and equipment, change in fair value of derivative liabilities, preferred shares, contingent consideration and other financial assets, and certain other non-operating (income) expenses. Expand The following table reconciles the Company's adjusted gross margin to gross margin before fair value changes to biological assets and inventories sold: The following table reconciles the Company's Free Cash Flow to net cash and restricted cash provided by (used in) operating activities: Third Quarter Fiscal 2025 Conference Call The Company will host a conference call to discuss its results with details as follows: Date: August 13, 2025 Time: 8:00 am Eastern Time To register for the conference call, please use this link: To ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 minutes before the start of the call. After registering, a confirmation will be sent through email, including dial in details and unique conference call codes for entry. Registration is open through the live call. To access the webcast: A replay of the webcast will be available within 24 hours after the conclusion of the call at and will be archived for a period of 90 days following the call. Non-IFRS Financial Measures This news release refers to certain financial performance measures (including adjusted gross margin, adjusted gross margin %, adjusted EBITDA and Free Cash Flow) that are not defined by and do not have a standardized meaning under IFRS as issued by the International Accounting Standards Board. Non-IFRS financial measures are used by management to assess the financial and operational performance of the Company. The Company believes that these non-IFRS financial measures, in addition to conventional measures prepared in accordance with IFRS, enable investors to evaluate the Company's operating results, underlying performance and prospects in a similar manner to the Company's management. As there are no standardized methods of calculating these non-IFRS measures, the Company's approaches may differ from those used by others, and accordingly, the use of these measures may not be directly comparable. Accordingly, these non-IFRS measures are intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS. Adjusted EBITDA is a non-IFRS measure that the Company defines as net income (loss) before: net of financing costs; income tax expense (recovery); depreciation, amortization, impairment, normalization of depreciation add-back due to changes in depreciable assets resulting from impairment charges, (gain) loss on disposal of property, plant and equipment (per the consolidated statement of cash flows); share-based compensation (per the consolidated statement of cash flows); share of loss (gain) from investments in associates including impairment loss; change in fair value of contingent consideration; change in fair value of derivative liabilities, other financial assets and preferred shares; expenditures incurred in connection with research and development ("R&D") activities (net of depreciation); unrealized gain on changes in fair value of biological assets; realized fair value on inventories sold and other inventory charges; provisions and net realizable value adjustments related to inventory and biological assets; government subsidies, insurance recoveries and other non-operating expenses (income); legal provisions (recoveries); incremental fair value component of inventories sold from acquisitions; ERP implementation costs; transaction costs; share issuance costs; and provision for expected credit losses . Adjusted EBITDA is intended to provide a proxy for the Company's operating cash flow and derive expectations of future financial performance for the Company, and excludes adjustments that are not reflective of current operating results. Adjusted gross margin is a non-IFRS measure that the Company defines as net revenue less cost of sales, before the effects of (i) unrealized gain on changes in fair value of biological assets; (ii) realized fair value on inventories sold and other inventory charges; (iii) provisions and impairment of inventories and biological assets; and (iv) provisions to net realizable value. Adjusted gross margin % is calculated by dividing adjusted gross margin by net revenue. Management believes that these measures provide useful information to assess the profitability of our operations as they represent the normalized gross margin generated from operations and exclude the effects of non-cash fair value adjustments on inventories and biological assets, which are required by IFRS. Free Cash Flow is a non-IFRS measure that the Company defines as net cash provided by or used in operating activities less the purchase of property, plant and equipment. Management believes this measure is a useful indicator of the Company's capacity to fund operations from internally generated cash flows, without the need for additional borrowings or use of existing cash reserves under normal operating conditions. The most directly comparable measure to adjusted EBITDA, calculated in accordance with IFRS is net income (loss) and beginning on page 5 of this press release is a reconciliation to such measure. The most directly comparable measure to adjusted gross margin calculated in accordance with IFRS is gross margin before fair value changes to biological assets and inventories sold and beginning on page 5 of this press release is a reconciliation to such measure. The most directly comparable measure to Free Cash Flow is net cash and restricted cash provided by (used in) operating activities, and beginning on page 5 of this press release is a reconciliation to such measure. About Organigram Global Inc. Organigram Global Inc. is a NASDAQ Global Select Market and TSX listed company whose wholly-owned subsidiaries include Organigram Inc., a licensed cultivator or cannabis and manufacturer of cannabis-derived goods in Canada. Through its recent acquisition of Collective Project, Organigram Global participates in the U.S. and Canadian cannabinoid beverages markets. Organigram is focused on producing high-quality, indoor-grown cannabis for patients and adult recreational consumers in Canada, as well as developing international business partnerships to extend the Company's global footprint. Organigram has also developed a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, Collective Project, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac-Supérieur, Québec, with a dedicated manufacturing facility in Winnipeg, Manitoba. The Company also operates two additional cannabis processing facilities in Southwestern Ontario; one in Aylmer and the other in London. The facility in Aylmer houses best-in-class CO2 and Hydrocarbon extraction capabilities, and is optimized for formulation refinement, post-processing of minor cannabinoids, and pre-roll production. The facility in London will be optimized for labelling, packaging, and national fulfillment. The Company is regulated by the Cannabis Act and the Cannabis Regulations (Canada). Forward-Looking Information This news release contains forward-looking information. Forward-looking information, in general, can be identified by the use of forward-looking terminology such as 'outlook', 'objective', 'may', 'will', 'could', 'would', 'might', 'expect', 'intend', 'estimate', 'anticipate', 'believe', 'plan', 'continue', 'budget', 'schedule' or 'forecast' or similar expressions suggesting future outcomes or events. They include, but are not limited to, statements with respect to expectations, projections or other characterizations of future events or circumstances, and the Company's objectives, goals, strategies, beliefs, intentions, plans, estimates, forecasts, projections and outlook, including statements relating to the Company's future performance, the Company's positioning to capture additional market share and sales including international sales, expectations for consumer demand, expected improvement to gross margins before fair value changes to biological assets and inventories, expectations regarding adjusted gross margins, adjusted EBITDA, Free Cash Flow and net revenue in Fiscal 2025 and beyond, expectations regarding cultivation capacity, the Company's plans and objectives including around the PDC, availability and sources of any future financing, availability of cost efficiency opportunities, the ability of the Company to fulfill demand for its revitalized product portfolio with increased staffing, expectations relating to greater capacity to meet demand due to increased capacity at the Company's facilities, expectations around lower product cultivation costs, the ability to achieve economies of scale and ramp up cultivation, expectations pertaining to the increase of automation and reduction in reliance on manual labour, expectations around the launch of higher margin dried flower strains, expectations around market and consumer demand and other patterns related to existing, new and planned product forms; expectations regarding the Company's acquisition, integration and synergy realization of Motif and Collective Project; expectations around FASTTM nanoemulsion technology; expectations regarding EU-GMP certification; timing for launch of new product forms, ability of those new product forms to capture sales and market share, estimates around incremental sales and more generally estimates or predictions of actions of customers, suppliers, partners, distributors, competitors or regulatory authorities; statements regarding the future of the Canadian and international cannabis markets and, statements regarding the Company's future economic performance. These statements are not historical facts but instead represent management beliefs regarding future events, many of which, by their nature are inherently uncertain and beyond management control. Forward-looking information has been based on the Company's current expectations about future events. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectations. These risks, uncertainties and factors include: general economic factors; international trade disputes sparked by tariffs and retaliatory tariffs or other non-tariff measures; changes to government laws, regulations or policies, including customs, tariffs, trade or environmental law, regulations or policies, or the enforcement thereof; receipt of regulatory approvals or consents and any conditions imposed upon same and the timing thereof; the Company's ability to meet regulatory criteria which may be subject to change; change in regulation including restrictions on sale of new product forms; change in stock exchange listing practices; the Company's ability to manage costs, timing and conditions to receiving any required testing results and certifications; results of final testing of new products; changes in governmental plans including those related to methods of distribution; timing and nature of sales and product returns; customer buying patterns and consumer preferences not being as predicted given this is a new and emerging market; material weaknesses identified in the Company's internal controls over financial reporting; the completion of regulatory processes and registrations including for new products and forms; market demand and acceptance of new products and forms; unforeseen construction or delivery delays including of equipment and commissioning; increases to expected costs; competitive and industry conditions; change in customer buying patterns; and changes in crop yields. These and other risk factors are disclosed in the Company's documents filed from time to time under the Company's issuer profile on the Canadian Securities Administrators' System for Electronic Document Analysis and Retrieval+ ('SEDAR') at and reports and other information filed with or furnished to the United States Securities and Exchange Commission ('SEC') from time to time on the SEC's Electronic Document Gathering and Retrieval System ('EDGAR') at including the Company's most recent management discussion and analysis ('MD&A') and annual information form. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this news release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward looking information is subject to risks and uncertainties that are addressed in the 'Risk Factors' section of the MD&A dated August 12, 2025 and there can be no assurance whatsoever that these events will occur. This news release contains information concerning our industry and the markets in which we operate, including our market position and market share, which is based on information from independent third-party sources. Although we believe these sources to be generally reliable, market and industry data is inherently imprecise, subject to interpretation and cannot be verified with complete certainty due to limits on the availability and reliability of raw data, the voluntary nature of the data gathering process, and other limitations and uncertainties inherent in any statistical survey or data collection process. We have not independently verified any third-party information contained herein.
Forbes
12-08-2025
- Forbes
Truckin' To 2030: Europe's Green Horizon For Medical Cannabis & Hemp
Europe's cannabis sector is undergoing a profound transformation—one driven by evolving regulations, changing social attitudes, and rising institutional investor interest. Germany, as the continent's largest economy, stands at the heart of this transition, leading a dual trajectory in both medical cannabis and industrial hemp. What was once niche is now positioned as a cornerstone of sustainable health, clean materials, and innovative investment opportunities. You might say that the European industry appears to be built to last. Market Overview and Segmentation Europe's cannabis landscape is divided into two distinct segments: THC‑containing cannabis (above 0.3% THC), regulated primarily for medical and sometimes adult-use purposes; and industrial hemp (below 0.3% THC), employed in foods, textiles, bioplastics, cosmetics, and construction. While sharing a botanical origin—Cannabis sativa L.—each operates under its own regulatory framework, supply chain, and market focus. Understanding this segmentation is essential for investors and policymakers evaluating risk and opportunity. Globally, the medical cannabis market was valued at approximately €4.5 billion in 2024 and is projected to reach over €62 billion by 2030—recording a staggering compound annual growth rate (CAGR) of 55%. Europe, fueled by demographic shifts and legal liberalization, is forecasted to be the fastest-growing region. Meanwhile, the industrial hemp market is poised to triple to around €15 billion by 2030, according to UNCTAD projections, driven by surging demand for climate-friendly materials and plant-based nutrition. Regulatory Developments The eyes of the world are on Germany, as it has emerged as the regulatory focal point in Europe. Its Cannabis Act (CanG), enacted in 2024, removed restrictive quotas and significantly expanded medical access. A complementary Medical Cannabis Act (MedCanG) is under development, emphasizing pharmacy-based distribution while tightening telemedicine channels. In parallel, a new Industrial Hemp Liberalization Act is expected in 2026, poised to eliminate outdated restrictions and modernize hemp production regulation. On the EU level, the classification of CBD as a Novel Food is opening doors to wellness and nutrition markets previously inaccessible for hemp producers. Growth in Medical Cannabis Since medical cannabis legalization in 2017, German patient numbers have soared—with 300,000 individuals receiving prescriptions in 2024, estimated to grow to 840,000 in 2025. By 2030, the market is expected to reach €650 million. Innovations in formulation—such as high-purity extracts, dronabinol pills, and cannabinoid pastilles—are expanding therapeutic use across neurology, chronic pain, and oncology. Major operators like SYNBIOTIC SE are leading the charge, developing standardized dosage forms and investing in regulated production. Global companies such as Tilray, Aurora, OrganiGram, and Canada's Sanity Group (via its partnership with OrganiGram) are deepening their European presence, underlining the continent's rising magnetism for international cannabis investors. Industrial Hemp as a Sustainability Engine Industrial hemp, long undervalued, is now recognized as a strategic asset in Europe's green economy. German industrial hemp sales grew from €526 million in 2023 to a projected €3 billion by 2032 (CAGR ~22%). Applications range from hemp-protein powders to sustainable building insulation and biodegradable packaging. EU regulatory shifts—especially Novel Food approvals for CBD—further enable consumer-facing products. Companies such as Hempro International and new-era ventures targeting hemp-based construction materials and plant-based supplements illustrate the growing breadth of the market. Investment Opportunities and Strategic Challenges Europe is increasingly attractive to North American capital. SYNBIOTIC SE exemplifies a diversified strategy, combining medical cannabis and hemp under a unified corporate model. The publicly traded holding company expects revenues to climb from €26 million in 2025 to €47 million by 2027, with positive EBITDA forecasted in 2026. This dual exposure provides a hedge against regulatory divergence and price compression in either sector. David Hyde, founder and CEO of Hyde Advisory & Investments, plays a pivotal role in monitoring and facilitating cannabis investments in Germany. Through his firm's expert brokerage services, Hyde navigates complex regulatory frameworks, matches strategic partners, and helps investors identify high-quality medical cannabis assets in the German market. Drawing from his firm's insights, Hyde notes: Germany's medical cannabis market continues to grow, albeit more slowly than Australia's. While German market competition is increasing, there is lots of room for new brand/category entrants with proper market research, understanding of developed cannabis markets and the right distribution partner(s)." Several industry leaders are confident that Europe represents the next major frontier for cannabis investment. As Boris Jordan, Executive Chairman of Curaleaf, put it, '[Europe is the next big market for cannabis after the U.S.]' Meanwhile, Irwin Simon, CEO of Tilray, emphasizes the scale of the opportunity: 'Germany's de-scheduling of cannabis opens the path to new opportunities in a potential $3 billion medical market; the European Union medical cannabis market is now projected to become $45 billion.' Constantin von der Groeben, founder of Demecan, reflects on Germany's growth momentum: 'The market is on a constant growth that is overwhelming,' while Beau Whitney, head economist at Whitney Economics, sees a broader European transformation underway: 'We can expect an accelerated expansion in the EU of legalised cannabis… If countries reform quickly, then the EU could supplant the U.S. as the major leader in global cannabis reform.' Yet investors must navigate risks: regulatory uncertainty (especially around telemedicine and CBD policy), intense price competition as production scales, limited banking integration, and macroeconomic volatility. The fragmented legal landscape further complicates capital deployment in cannabis-related ventures. Why Legalization Is Working The legalization model in Europe—and particularly in Germany—has shown measurable success. Its framework promotes transparency, standards for safety and quality, and integration into conventional health systems. The emphasis on licensing, standardized extracts, and court-regulated pharmacies mirrors a methodical approach, providing market certainty for investors and patients alike. Moreover, reform frameworks that prioritize illicit-market conversion—such as transitioning traditional, unregulated growers into legal cooperatives—mirror best practices championed by analysts like Whitney Economics. This conversion aligns economic incentives, reduces social harms, and demonstrates the sustainability of the legal regime. Outlook to 2030 As of 2025, both medical cannabis and industrial hemp are poised to become multibillion-euro pillars of Europe's economy. By 2030, medical cannabis in Europe could exceed €10 billion, while industrial hemp ascends as an eco-driven mainstay. Companies rooted in innovation, regulatory compliance, and product diversification will lead market consolidation. Germany will remain the driving force behind this evolution—acting as the regulatory pioneer and investment hub for cannabis in Europe. Institutional and private investors seeking long-term value should consider pan-European platforms that bridge both cannabis segments, such as publicly traded SYNBIOTIC SE. Their IFRS-audited integrated model reflects the shift to a new chapter in medicine and an innovative sustainable economy. END NOTES: CanG Gesetz 2024 – UNCTAD 2022 – Cannabissciencetech 2024 – CannaMonitor 2025 – Credence Research – Grand View Research – IMARC Group – Luminorecruit 2025 – MJBizDaily 2024 – Novel Food – OrganiGram/Sanity Group 2024 – Research And Markets 2024 – Reuters 2024 – Statista – Weedman 2025 –
